Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Zenas BioPharma, Inc.
Zenas BioPharma, Inc. News
Mar 31, 2025 - prnewswire.com
ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Mar 26, 2025 - prnewswire.com
ZBIO Investor News: Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Mar 25, 2025 - globenewswire.com
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Mar 24, 2025 - accessnewswire.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation - ZBIO
Zenas BioPharma, Inc. Quantitative Score
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Zenas BioPharma, Inc. Earnings & Revenue
Zenas BioPharma, Inc. Financials
Table Compare
Compare ZBIO metrics with: | |||
|---|---|---|---|
Earnings & Growth | ZBIO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ZBIO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ZBIO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ZBIO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Zenas BioPharma, Inc. Income
Zenas BioPharma, Inc. Balance Sheet
Zenas BioPharma, Inc. Cash Flow
Zenas BioPharma, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Zenas BioPharma, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Zenas BioPharma, Inc. Executives
| Name | Role |
|---|---|
| Mr. Joseph L. Farmer | Chief Operating Officer & President |
| Ms. Jennifer A. Fox | Chief Business Officer & Chief Financial Officer |
| Dr. Tanya Z. Fischer M.D., Ph.D. | Head of Research & Development and Chief Medical Officer. |
| Mr. Leon Oliver Moulder Jr., M.B.A. | Chief Executive Officer & Chairman of the Board |
| Ms. Caroline Chevalier | Chief Human Resources Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Joseph L. Farmer | Chief Operating Officer & President | Male | 1972 | 668.97K |
| Ms. Jennifer A. Fox | Chief Business Officer & Chief Financial Officer | Female | 1972 | 490.06K |
| Dr. Tanya Z. Fischer M.D., Ph.D. | Head of Research & Development and Chief Medical Officer. | 332.54K | ||
| Mr. Leon Oliver Moulder Jr., M.B.A. | Chief Executive Officer & Chairman of the Board | Male | 1957 | 126.92K |
| Ms. Caroline Chevalier | Chief Human Resources Officer | Female | -- |
Zenas BioPharma, Inc. Insider Trades
| Date | 17 Mar |
| Name | von Moltke Lisa |
| Role | Officer |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 18 Feb |
| Name | MOULDER LEON O JR |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 25000 |
| Date | 7 Feb |
| Name | Xiao Ting |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 10000 |
| Date | 16 Dec |
| Name | Fox Jennifer A. |
| Role | See Remarks |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 8125 |
| Date | 16 Dec |
| Name | Oliveira Orlando |
| Role | Chief Commercial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 7775 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 17 Mar | von Moltke Lisa | Officer | Disposed | 0 | |
| 18 Feb | MOULDER LEON O JR | Chief Executive Officer | Acquired | P-Purchase | 25000 |
| 7 Feb | Xiao Ting | Director | Acquired | P-Purchase | 10000 |
| 16 Dec | Fox Jennifer A. | See Remarks | Acquired | A-Award | 8125 |
| 16 Dec | Oliveira Orlando | Chief Commercial Officer | Acquired | A-Award | 7775 |